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Human chorionicgonadotropin (hCG) is aglycoprotein hormone composed oftwodissimilar
subunits, ao and P. Nicks ormissingpeptide linkages have been found in the ,B44-52 region ofthe
p-subunit of hCG, whether from pregnancy or trophoblast disease. This article reviews recent
reports about the location of nicks in hCG, their origin and occurrence, their effects on the
steroidogenic and receptor-binding activities of hCG, and on the immunological activities of
hCG and its free p-subunit. Taken together, the reports show: (1) nicks occur primarily
between 047 and p48, and to a lesser extent between 044 and p45; (2) the extent of nicking in
hCG samples varies widely, from undetectable to 100 percent of molecules; (3) nicks greatly
reduce the steroidogenic activity ofhCG in vitro (nicked molecules have less than 20 percent of
the activity ofthe intact hormone); (4) nicks may occur at the trophoblast-myometrial interface
orin the circulation bythe action ofhuman leucocyte elastase orsimilar leucocytic protease; (5)
hCG testing kits using dimer-specific antibodies may not detect nicked molecules and may give
different results from those using other antibodies; (6) hCG international reference prepara-
tions and the CR series of hCG standards are variably nicked (10 percent to 20 percent),
complicating the problem of discordant hCG results in nick-sensitive assays; (7) results from
commonly used immunoassays for measurement ofthe hCG free P-subunit vary by as much as
tenfold because some ofthe antibodies employed do not detect nick free p-subunit.
BACKGROUND
Human chorionic gonadotropin (hCG) is a glycoprotein hormone composed of
two dissimilar subunits, a (92 residues) and ,B (145 residues), joined non-covalently.
hCG is produced by the trophoblast in pregnancy and trophoblast disease. The
a-subunit of hCG has the same peptide sequence as the a-subunit of the pituitary
glycoprotein hormones. The P-subunit of hCG is similar to the P-subunit of human
luteinizing hormone (hLH) (80 percent sequence homology). The P-subunits ofhCG
and hLH are responsible for directing binding of both hormones to their joint
receptor.
hCG levels are used to examine the progress of pregnancy, to follow the evacua-
tion ofhydatidiform mole, and to follow the success ofchemotherapy in women with
persistent trophoblast disease (invasive mole and choriocarcinoma). In addition to
hCG, a small amount of uncombined a-subunit (free a-subunit) and uncombined
P-subunit (free P-subunit) are secreted by trophoblast tissue [1-7]. Levels of free
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13-subunit in pregnancy serum are one five-hundredth to one one-hundredth ofthose
of hCG (from seven weeks to term). Higher levels of free 1-subunit are present in
serum from patientswith hydatidiform mole (one one-hundredth to one-tenth ofthe
hCG levels), and still higher levels in women with persistent trophoblast disease
(one-twentieth to one-fourth of the hCG levels) [7-12]. Measurements of free
13-subunit are now used in the diagnosis and management ofhydatidiform mole and
persistent trophoblast disease [8,9].
In 1973, Shome and Parlow [13] discovered nicks or missing peptide linkages at
different sites between residues 44 and 49 on hLH 1-subunit. More recently, the
nicks have been located to between 1-subunit residues 44 and 45, 47 and 48, or 48
and 49 on hLH [14,15]. These nicks diminishthebiological activityofhLH. As shown
by Ward and colleagues [14], highly nicked hLH preparations have 40 percent lower
biological activity than less nicked samples. In 1988, Bousfield and Ward [16] found
that hLH cleaved by endoproteinase Arg-C (nicks at an adjacent site, 1B43-44) also
has diminished biological activity.
In 1988, Nishimura and colleagues used electrophoresis and immunoblotting
procedures to examine a urine hCG sample from a woman with trophoblast disease
[17]. On gels, a band migrating in the position of standard hCG 13-subunit
(Mr = 35,000) was detectedwith 1-subunit C-terminalpeptide antisera. Afterreduc-
tion of the disulfide bridges, however, a faster migrating band (Mr = 24,000) was
detectedwith this antisera. Thisfindingwas the first indication ofmissing linkages in
hCG. Since this time, ten reports have been published [4,18-26], originating in
France, Japan, and the U.S.A. The results are reviewed here. Findings include the
sitesofnicksin hCG [4,18-20,21,23], theoccurrenceofnicksin individualhCGsamples
[4,22], theoriginofnicksinhCG [24], theeffectofnickson thebiologicalactivityofhCG
[19,22], the recognition ofnicked hCG by different immunoassays [22,26], and nicks in
hCGfree 1-subunit [20,25].
SITES OF NICKS IN HCG
In July 1988, Nishimura and colleagues published electrophoresis results indicat-
ing nicks in an individual trophoblast disease hCG sample. Four weeks later, Bidart
and colleagues published their findings [18], which demonstrated nicks in hCG
purified from a crude pregnancy urine preparation ("Pregnyl" from Organon, crude
preparation from large number of pregnancy urines). Using sequence analysis,
Bidart and colleagues demonstrated a single nickbetween 1-subunit residues 47 and
48, in this preparation. In the following year, Lustbader, Birken, and colleagues
performed similar experiments, purifying hCG from Organon crude and examining
the N-terminal sequences [21]. They found nicks at two of the three hLH cleavage
sites, between 1-subunit residues 44 and 45, and between 1-subunit residues 47 and
48 (Fig. 1). Recently, Birken and colleagues examined the sequence of eight
international hCG standards [24]. These included the first I.R.P. (international
reference preparation) for immunoassay, and the CR series (CR117, 119, 121, 123,
125, and 127) distributed by the National Institutes of Health. To determine
accurately the sites and extents ofnicking, Birken and colleagues isolated the nicked
13-subunit of hCG by reverse-phase chromatography before doing N-terminal se-
quence analysis. Preparation CR119 (same asfirst I.R.P.) was shown tobe 10percent
nicked (at 1347-48 or 1344-45), preparation CR127 to be 20 percent nicked, and the
628NICKS IN hCG
TABLE 1
N-Terminal Sequence Analysis of1-Subunit ofPurified hCG
Proportion
N-Terminal Sequence Detected Starting at ofNicked hCG
Sample Molecules
Code p1 145 147 148 (%)
hCGPurifiedfrom IndividualPregnancy Unnes
P1 1.0 0 0 0 0
P2 1.0 0 0 0.35 35
P3 1.0 0 0 0.59 59
P4 1.0 0 0 0.86 86
P5 1.0 0 0 0.58 58
P6 1.0 0 0.55 0.57 100
hCGPunfiedfrom Individual TrophoblastDiseasePatient Urines
Ml 1.0 0 0 0.15 15
M2 1.0 0 0 0 0
M4 1.0 0 0 1.0 100
Cl 1.0 0.23 0 0.39 62
C2 1.0 0.51 0 0.45 96
C3 1.0 0 0 0.24 24
C5 1.0 0 0 1.28 100
N-terminal sequence determined for 15 consecutive amino acid residues, and compared with the
known peptide structures ofthe a- and 1-subunits ofhCG. The amountofeach sequence was estimated
from the concentration ofPTH-amino acids (pmol), and was normalized to the sequence starting at 31.
Proportion of molecules nicked is the percentage of peptides starting at 145 or 48 compared with ,13
[23].
other standards to be nicked within this 10 to 20 percent range. These findings show
hCG isolated from large pools of pregnancy urine (i.e., Organon crude) is, on
average, 10 to 20 percent nicked at one oftwo sites, p44-45 or p47-48.
The studies with hCG standards or hCG purified from Organon crude gave a
general idea about the sites and extent ofnicking. They said nothing, however, about
individual samples. Are individual samples all 10 to 20 percent nicked or are some 0
percent and others 100 percent nicked? Are individual samples nicked at both
p44-45 and 47-48, or are some nicked at one site and others at the second site? To
addressthis issue, Kardana andcolleagues [23] examinedthe hCGinurinesfromfive
individuals with first trimester (P1, P2, P3, P5, P6) and from one individual with
second trimester pregnancy (P4), from three individualswith complete hydatidiform
mole (Ml, M2, M4), and from four women with advanced choriocarcinoma. They
used classical solvent extraction and chromatographic methods topurify hCG. Using
N-terminal sequence analysis (Table 1) Kardana and colleagues [23] showed that 11
ofthe 13 individual urine samples were nicked. Most sampleswere nicked atjust one
site, p47-48 (three of the 11 were also nicked at p44-45 or ,46-47), and that the
extent of nicking in individual urine samples varied widely (0 to 100 percent). In
conclusion, hCG standards purified from pooled urines, and clinical hCG prepara-
tions like "Pregnyl," represent an average mixture (10 to 20 percent nicking at
p44-45 or p47-48), and so, in extent and site of nicking, are not necessarily
representative of individual samples, which display a wide variation in the extent of
nicking (0 to 100 percent nicked, primarily at one site).
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OCCURRENCE OF NICKS IN INDIVIDUAL hCG SAMPLES
Electrophoresis of reduced hCG molecules and immunoblotting with 1-subunit
C-terminal peptide antisera was used in 1988 to identify nicked hCG in individual
and pooled urine samples [17,18]. In 1989, Cole and colleagues used the same
methods to identify nicked hCG in individual pregnancy and trophoblast disease
serum samples [4]. Shortly thereafter, Puisieux and colleagues confirmed this
finding, byidentifying nicked hCG in the serum from four individuals with choriocar-
cinoma [20]. Recently, electrophoresis and immunoblotting were used to examine
nicks in 34 urine and serum samples from patients with pregnancy and trophoblast
disease [22]. A fast-migrating band (Mr= 24,000), indicative of nicked hCG, was
observed in 71 percent of pregnancy urine samples and 80 percent of the matching
sera, and in 82 percent of trophoblast disease urine samples and in seven of seven
matching sera. These findings show that hCG molecules are, to some extent, nicked
in most pregnancy and trophoblast disease serum and urine samples. The extent of
nicking in serum is not significantly different to that in urine based on these
semi-quantitative electrophoresis and immunoblotting techniques. This was con-
firmed by immunoassays for nicked hCG (described below). While realizing that
individual hCG samples vary widely, the 10 to 20 percent range, as indicated by
standard or pooled preparations, may reflect the average extent of nicking in
individual pregnancy hCG serum and urine samples.
THE ORIGIN OF NICKS IN hCG
Since nicks are present in both serum and urine, it is likely that nicking occurs
inside the trophoblast cell, at the time of secretion, or in the circulation. Human
leucocyte elastase (HLE) is a protease that cleaves after glycine, valine, or leucine
residues within exposed hydrophobic regions ofproteins [27]. Nicks in hCG occur at
,B44-45 (Val-Leu) and ,B47-48 (Gly-Val) (Fig. 1). The nicks occur within an amphi-
pathic intercysteine loop on 1-subunit. An amphipathic loop is hydrophilic on one
side and hydrophobic on the other, making it a good substrate for HLE with an
exposed hydrophobic face. Leucocytes and HLE are known to be present in high
concentrations at the trophoblast-myometrial interface and at the choriocarcinoma-
normal tissue interface [28]. To test the hypothesis that HLE may play a role in
nicking of the loop region, Birken and colleagues [24] used sequence analysis to
investigate the cleavage ofCR127 standard hCGby HLE. Asfound, after a two-hour
period, HLE cleaved 30 percent ofhCG molecules at ,B44-45, and at no other site on
the ax- or ,B-subunit. With longer incubations, further cleavages occurred at 144-45,
147-48, and 148-49. We conclude that HLEmaybe responsible fornicks at 144-45 in
hCG preparations. The identity of the enzyme that nicks at 147-48 is less certain.
While HLE may be involved, it appears more likely that other enzymes with
specificities similar to HLE, possibly also located at the trophoblast-myometrial and
choriocarcinoma-normal tissue interfaces, nick at this site.
EFFECT OF NICKS ON THE BIOLOGICAL ACTIVITY OF hCG
Sakakibara and colleagues [19] purified hCG 1-subunit from a pool ofpregnancy
urines and separated nicked from non-nicked hCG 13-subunit molecules by reverse
phase chromatography. Nicked hCG 13-subunit was then recombined with a-subunit.
The product (a:nicked 1) had less than one percent of the steroidogenic activity of
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FIG. 1. The peptide sequences ofhCG 3-subunit, showing disulfide linkages as established by Mise and
Bahl [31], and nicks at 147-48 and 144-45.
natural hCG. Cole and colleagues [22] used HLEto generate nicked CR127standard
hCG. The product had approximately 20 percent of the steroidogenic activity of
non-treated CR127 standard hCG. The discrepancy in these results may come from
the use ofdifferent hCG preparations, or it may be due to abnormal combination of
Sakakibara and colleagues' nicked ,-subunit preparation, or to damage to this
preparation by the trifluoroacetic acid used in the reverse phase procedure. All told,
a single nick at 144-45 or ,347-48 dramatically reduces the steroidogenic activity of
hCG.
Cole and colleagues [22] also looked at the steroidogenic and receptor binding
activities of eight individual hCG preparations (Table 2). No correlation was found
between the proportion of intact or non-nicked hCG molecules in the individual
preparations and their ability to displace 1"I-hCG in binding the hCG/LH receptor.
A close correlation was found, however, between the proportion of intact (non-
nicked) molecules and their steroidogenic activity in vitro (correlation coefficient
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TABLE 2
The Biological and Receptor Binding Activities of Individual Pure Preparations ofhCG
Proportion of
Non-Nicked hCG Concentration Steroidogenic Activity Radioreceptor
Moleculese byAmino Acid Assay
Sample (%) Analysis, ,ug/ml pLg/ml tg/tLg hCGb EC50c
hCGPurifiedfrom IndividualPregnancy Urines
P1 100 620 620 1.Od 1.0e
P3 41 530 250 0.48 1.6
P4 14 2,450 1,250 0.51 1.7
P5 42 1,460 730 0.50 1.1
hCGPurifiedfrom Individual Trophoblast DiseasePatient Urines
Ml 85 1,090 950 0.87 1.3
M2 100 1,490 1,760 1.2 0.82
Cl 38 4,300 2,490 0.58 2.2
C5 0 2,100 420 0.20 1.6
Steroidogenicactivitywas determined in the isolated ratluteal cell progesterone test, and radiorecep-
tor assay activity in the competitive binding assay using homogenated luteinized rat ovaries.
aThe proportion ofnon-nicked hCG molecules (percentage) is calculated as 100 minus percentage of
nicked molecules (from Table 1).
bhCG determined by amino acid analysis
cValues are the concentration (pg/ml by amino acid analysis) necessary to displace 50 percent of
"I-hCG in binding receptor; values are normalized to result for P1 hCG.
dIn a regression analysis, steroidogenic activity (pLg/pg hCG) versus percentage non-nicked hCG,
correlation coefficient wasgreater than 95 percent.
eln a regression analysis, receptor binding activity (EC50 in radioreceptor assay) versus percentage
non-nicked hCG, significant correlation not observed (correlation coefficient = 68 percent)
>95 percent). It was estimated (intercept of regression line) that the nicked
components of the individual preparations had approximately 24 percent of the
steroidogenic activity of non-nicked molecules. This estimate supported the studies
with HLE-cleaved standard hCG, which suggested that nicked hCG had about 20
percent ofthe activity ofnon-cleaved molecules. These findings indicated that nicks,
which do not have a major effect on hCG receptor binding, were an important cause
of discordance in steroidogenic activity between individual hCG preparations. It is
concluded that nicked molecules, a component ofmost hCG preparations, have low
steroidogenic activity and could antagonize hCG action.
RECOGNITION OF NICKED hCG BY DIFFERENT IMMUNOASSAYS
Our group showed that monoclonal antibodies specific for dimer hCG have much
lower affinity for nicked hCG [22,24,26]. This finding was an important observation
since this type of antibody is commonly used in kits for the clinical measurement of
hCG and could result in errors when nicked molecules were a major component of
the hCG sample. Table 3 shows the results of recent tests of eight different
immunoassays [26]. Each was used to measure the hCG level at six different
concentrations in three hCG standards. These were hCG standard batch CR127 (20
percent nicked), hCG batch CR127 incubated for 21 hours with HLE (90 percent
nicked), and C5 individual hCG preparation (100 percent nicked). Results were
plotted andvariation invalueswas examined at the level corresponding to50 percent
of maximum response. As shown, nicks only minimally (+29 percent) affect the
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TABLE 3
Recognition ofNicked and Non-Nicked hCG by Different Immunoassay
CR127 hCG
CR127 hCG 21-hour HLE C5 hCG
(20 percent Nicked) (90 percent nicked) (100 percent nicked)
Immunoassay (%) (%) (%)
2119-12/BP052 anti-a:anti-,-peroxi- 100 107 71
dase sandwich assay
Hybritech Tandem-R anti-a:`1I- 100 114 129
anti-n sandwich assay
Organon NML anti-p C-terminus:'1I- 100 108 116
anti-P sandwich assay
Biomerica hCGanti-p:'`I-anti-p 100 117 117
sandwich assay
Diagnostic Products anti-P radioim- 100 118 67
munoassay
Amersham Amerlex-M anti-, radio- 100 95 98
immunoassay
B109/BP052 anti-hCG: anti-p-peroxi- 100 522 1,580
dase sandwich assay
Serono MAIA clone anti-hCG:'251- 100 465 1,370
anti-p sandwich assay
hCG standards were prepared 20 to 100 percent nicked. These were hCG standard CR127 hCG,
standard CR127 further nicked by incubation 21 hours with HLE, and individual hCG preparation C5.
Each standard was tested in each immunoassay kit at six different dilutions (between 0.25 and 200
mg/ml). Values are relative concentrations (percentage of hCG standard CR127 level) needed for 50
percent maximum response.
potency of hCG in kits using anti-a:anti-P, anti-,B C-terminus:anti- and anti-p:
anti-, sandwich protocols, and in hCGI3 RIAs. Nicks, however, have averybig effect
on the potency of hCG in kits using antibodies to hCG dimer (anti-hCG:anti-1
sandwich assays). As much as 16 times more nicked hCG was needed to achieve a
similar response as non-nicked hCG (Table 3). The assays using an hCG dimer
antibody include the widely used Serono MAIA clone kit and the B109 anti-hCG
assay from Columbia University. This latter assay has been distributed by Drs.
Canfield and O'Connor at Columbia University to a large number of test centers in
North America for the ultrasensitive detection ofearly pregnancy hCG levels [29]. A
survey of different quantitative hCG kits available in North America revealed that
approximately one-quarter utilize an hCG dimer antibody. Nicking ablates the
biological activity of hCG [19,22]. Thus, levels of non-nicked hCG (determined by
Serono MAIA clone, B109 anti-hCG or other immunoassays with similar specifici-
ties) could be more representative ofbiologically active hormone than levels oftotal
hCG (measured with the other immunoassays) and may be preferable in situations
where knowing the potency ofhCG is critical.
Using the B109 anti-hCG dimer assay to measure the level ofnon-nicked, and the
Hybritech Tandem assay to measure total hCG, attempts were made to assess the
extent of nicking in pregnancy and trophoblast disease hCG samples [22]. By these
methods, approximately 25 percent nicking was indicated in 38 pairs of serum and
urine samples. Consistent with sequence analysis studies with individual urine hCG
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samples (Table 1), very wide variation in the extent of nicking (0 to 94 percent of
molecules) was indicated.
We conclude that hCG kits might be categorized as either immunoassays for total
hCG, which measure nicked plus non-nicked molecules, or as immunoassays for
intact hCG, which only detect non-nicked molecules. The existence of these two
categories of hCG kits may be a major cause of discordance in results between
different immunoassays and the cause ofconfusion in interpreting assayresults from
different test centers. The two categories of kits could have separate applications.
Total hCG kits might be optimal for general pregnancy, cancer, and trophoblast
disease applications. Intact hCG kits might be optimal for assessing the level of
biologically active hCG; thus they may be preferable for monitoring women with
threatened abortion or other situations requiring assessment ofhCG potency.
NICKS IN hCG FREE 1-SUBUNIT
Studies at Yale University [4] and at other centers throughout the world [3,5,7,8-
12] show a higher free 13-subunit to hCG ratio in sera from patients with persistent
trophoblast disease than in that from patients with hydatidiform mole, and a higher
free 13-subunit to hCG ratio in the latter than in normal seven- to 40-week pregnan-
cies. An outcome ofthese reports is the availabilityofmonoclonal antibodies andkits
using these antibodies for specifically measuring free 13-subunit, and the testing for
free ,B-subunit at trophoblast disease centers. Reports from different centers on the
free ,B-subunit to hCG ratio in serum, however, varywidely. Reports on the average
free 1-subunit to hCG ratio for persistent trophoblast disease, for instance, range
from 2.6 percent [11] to 37 percent [10]. The discrepancy in reported levels has
deterred physicians from using these tests and has limited the interpretation of
results [25,30].
Kardana and Cole [25] investigated the cause of the wide variation in free
1-subunit to hCG ratios. They determined levels in serum using two different free
1-subunit immunoassays. The first assay used the monoclonal antibody lE5. An
immunoassay using antibody 1E5 was employed in several reports on free ,3-subunit
levels, by Khazaeli and colleagues ([8], and four other articles), by Thomas and
colleagues ([11], and one other article), and by our laboratory [2,4,6]. The second
assay used monoclonal antibody FBT11. This assay has also been used in several
reports on free 1-subunit levels, by Ozturk and colleagues ([3,9], and four other
articles). The two assays were carried out by similar procedures, using the free
13-subunit specific monoclonal as capture antibody, and anti-13 antiseraperoxidase to
detect bound molecules. As found (Table 4), qualitatively the two immunoassays
gave similar results (higher percentage free 1-subunit in trophoblast disease), but,
quantitatively, the values differed up to tenfold. As such, results are assay-specific
and not interchangeable.
Puisieux and colleagues [20] examined the free 13-subunit produced in trophoblast
disease and found that it was more extensively nicked than hCG. Kardana and
colleagues [25] prepared 0 and 100 percent nicked 13-subunit standards and tested
the recognition ofnicked molecules in the lE5 and FBT11 free 1-subunit immunoas-
says. The assay using antibody 1E5 did not recognize nicked 13-subunit (level for
nicked 1-subunit was 4 percent ofnon-nicked level), detecting only intact 13-subunit
molecules. The immunoassay using antibody FBT11, however, gave similar results
with nicked and non-nicked standards (nicked 1-subunit level was 96 percent of
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TABLE 4
Testing ofIndividual Serum Samples for hCG and Percentage ofFree P-Subunit
hCG Assay Free b-Subunit Assays
2119-12/BP052 1E5/BP052 FBT11/BPO52
Anti-a:Anti- Anti-Free 1:Anti-1 Anti-Free 13:Anti-13
Sandwich Assay Sandwich Assay Sandwich Assay
Diagnosis (p,g/ml (mIU/ml)a) (% ofhCG level)b (% ofhCG level)b
First trimester pregnancy, 5 weeks
First trimester pregnancy, 6weeks
First trimester pregnancy, 6weeks
First trimester pregnancy, 7weeks
First trimester pregnancy, 7weeks
First trimester pregnancy, 7weeks
First trimester pregnancy, 7weeks
First trimester pregnancy, 7weeks
First trimester pregnancy, 8 weeks
First trimester pregnancy, 8weeks
Mean + S.D.
Partial mole, pre-evacuation
Partial mole, pre-evacuation
Partial mole, pre-evacuation
Partial mole, pre-evacuation
Partial mole, pre-evacuation
Partial mole, pre-evacuation
Complete mole, pre-evacuation
Complete mole, pre-evacuation
Complete mole, pre-evacuation
Complete mole, pre-evacuation
Complete mole, pre-evacuation
Complete mole, pre-evacuation
Mean ± S.D.
Invasive mole, pre-therapy
Invasive mole, pre-therapy
Invasive mole, pre=therapy
Choriocarcinoma, pre-therapy
Choriocarcinoma, pre-therapy
Choriocarcinoma, pre-therapy
Mean + S.D.
7.3 (68,000)
2.0 (18,600)
4.1 (38,100)
8.9 (83,000)
2.5 (23,000)
2.4 (22,000)
5.8 (54,000)
2.5 (23,000)
15.5 (144,000)
3.9 (36,000)
5.5 + 4.2
60 (558,000)
30 (279,000)
9.6 (89,000)
19.6 (182,000)
3.1 (28,000)
195 (1,810,000)
9.0 (84,000)
61 (567,000)
146 (1,360,000)
116 (1,080,000)
49 (456,000)
49 (456,000)
62 ± 60
11.3 (105,000)
0.65 (6,050)
19 (177,000)
121 (1,125,000)
8.7 (81,000)
8.8 (82,000)
28 ± 46
1.0
1.0
0.25
0.17
0.53
1.7
0.97
0.28
0.43
0.26
0.66 ± 0.49
0.43
0.71
0.20
1.2
0.16
2.7
0.29
0.44
0.06
0.09
0.83
0.11
0.61 + 0.76
0.91
2.2
0.89
2.3
0.18
0.54
1.2 ± 0.86
0.55
0.45
0.37
0.52
0.57
0.66
0.67
0.79
0.58
0.13
0.53 ± 0.18
2.12
18.6
1.95
13.7
1.6
5.6
1.3
4.4
0.89
1.3
7.3
3.3
5.2 ± 5.6
11.6
7.4
14.7
7.2
2.7
25.7
11.6 + 8.0
aCalculated assuming 70 ,ug = 650 IU (orljig = 9.3 IU), as established for preparing the first I.R.P.
for immunoassay [32]
bFree p-subunit level(p,g/ml)presented as apercentage ofhCG level(,ug/ml)
non-nicked value), measuring total P-subunit. Kardana and colleagues [25] attrib-
uted the discordance in values seen with 1E5 and FBT11 assay results, and possibly
the discordance with other free a-subunit immunoassay results, to differences in
recognition of nicked free P-subunit molecules. Using the 1E5 assay, which only
detects non-nicked molecules, arelativelysmall differencewas observed invalues for
pregnancy and persistent trophoblast disease (twofold). Using the FBT11 assay,
which detects total free p-subunit, amuchbigger difference isobserved (twentyfold).
We infer that the FBT11 or total free p-subunit type of assay is preferable for the
differential diagnosis of pregnancy, hydatidiform mole, and persistent trophoblast
disease.
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GENERAL CONCLUSIONS
The finding ofawidevariation in the extent ofpeptide bond nicks in hCG isolated
from both pregnancy and trophoblast disease urines was surprising. The additional
discovery that nicks not only diminished the biological activity of hCG but also
reduced the immunoreactivity of the hormone as measured by common monoclonal
antibodies gave this finding greater importance. The potential diagnostic values of
measurements ofnicking are asyetunknown, butthenecessitytoevaluate measuring
systems for sensitivity to nicked molecules is a serious and urgent consideration.
The finding of nicks in hCG may help to explain the variable biological activity of
different hCG samples and standards, the discordant results obtained for hCG
betweendifferent immunoassays, and thewidevariationinfree ,-subunit immunoas-
say results. The origin of the nicks is still uncertain, and the possibility that nicks
control hCG activity by deactivation needs to be considered. The possibility that
nicked molecules have other, non-hCG, activities, such as immunosuppressive or
growth factor activities should also be investigated.
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